Automate Your Wheel Strategy on SNY
With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNY
- Rev/Share 17.7381
- Book/Share 30.1556
- PB 2.8932
- Debt/Equity 0.2841
- CurrentRatio 1.3662
- ROIC 0.0601
- MktCap 105968736197.4
- FreeCF/Share 0.6248
- PFCF 68.7216
- PE 34.0226
- Debt/Assets 0.1596
- DivYield 0.0448
- ROE 0.0848
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SNY | Exane BNP Paribas | -- | Outperform | -- | $65 | April 15, 2025 |
| Initiation | SNY | Goldman | -- | Neutral | -- | $65 | March 21, 2025 |
| Upgrade | SNY | Deutsche Bank | Sell | Hold | -- | -- | Jan. 30, 2025 |
News
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi
Read More
Sanofi buys US biopharma group Blueprint in $9.1 bln deal
Published: June 02, 2025 by: Reuters
Sentiment: Positive
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday.
Read More
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
Published: June 02, 2025 by: WSJ
Sentiment: Positive
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Read More
Itepekimab Failure A Setback For Sanofi And Regeneron
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Negative
Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak sales potential looks like a best-case scenario for itepekimab. Regeneron faces a greater impact, as it is losing an important growth driver in the second half of the decade.
Read More
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
Read More
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
MORRISTOWN, N.J. , May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster.
Read More
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
Read More
Sanofi to Buy Vigil Neuroscience for About $470 Million
Published: May 21, 2025 by: WSJ
Sentiment: Positive
Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer's disease to the French pharmaceutical company's pipeline.
Read More
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 -
Read More
Sanofi to acquire Vigil Neuroscience in $470 million deal
Published: May 21, 2025 by: Reuters
Sentiment: Positive
Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.
Read More
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline
Read More
Sanofi to invest at least $20 billion in the US through 2030
Published: May 14, 2025 by: Reuters
Sentiment: Positive
French drugmaker Sanofi said on Wednesday it plans to invest at least $20 billion in the United States through 2030, which includes an increase in research and development spending and the allocation of billions of dollars to US manufacturing.
Read More
Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
Published: May 14, 2025 by: PRNewsWire
Sentiment: Neutral
MORRISTOWN, N.J. and CAMBRIDGE, Mass.
Read More
Sanofi: Investing in prevention builds Europe's health and competitiveness
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe's strategic agenda. At the European Economic Congress in Katowice, discussions reflected both the Presidency's efforts to strengthen healthcare resilience and drive digital transformation, and a broader consensus that prevention, innovation, and life science leadership must be at the core of Europe's long-term strategy. Sanofi's experts highlighted the pivotal role of immunization, respiratory health, and sustainable innovation in building a healthier and competitive Europe.
Read More
Press Release: Annual General Meeting of April 30, 2025
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders' Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa.
Read More
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy.
Read More
Sanofi (SNY) Q1 2025 Earnings Call Transcript
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Sanofi (NASDAQ:SNY ) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research & Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Conference Call Participants Richard Vosser - JPMorgan Luisa Hector - Berenberg Colleen Garvey - Guggenheim Ben Jackson - Jefferies Peter Verdult - BNP Exane Jo Walton - UBS Graham …
Read More
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
Published: April 18, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Read More
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Published: April 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents …
Read More
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Read More
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Published: April 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MS Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026 Paris, …
Read More
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
Read More
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for two rare diseases, warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD).
Read More
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Published: April 01, 2025 by: CNBC Television
Sentiment: Negative
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Read More
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
Read More
US FDA approves Sanofi's bleeding disorder therapy
Published: March 28, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents blood from clotting properly, the regulator said on Friday.
Read More
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.
Read More
About Sanofi (SNY)
- IPO Date 2002-07-01
- Website https://www.sanofi.com
- Industry Drug Manufacturers - General
- CEO Mr. Paul Hudson
- Employees 82878